{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Denver&page=3&state=Colorado", "query": { "state": "Colorado", "city": "Denver", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 7451, "total_pages": 746, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Denver&page=4&state=Colorado&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Denver&page=2&state=Colorado&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T20:47:26.540Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00950963", "title": "Nurse Telephone Management of Cholesterol in Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 1 Diabetes", "Type 2 Diabetes" ], "interventions": [ { "name": "Phone Counseling", "type": "BEHAVIORAL" }, { "name": "Standard Clinical Care", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Denver Health and Hospital Authority", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": null, "sex": "ALL", "summary": "17 Years and older" }, "enrollment_count": 762, "start_date": "2005-09", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2015-04-28", "last_synced_at": "2026-10-30T20:47:26.540Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00950963" }, { "nct_id": "NCT01055314", "title": "Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Rhabdomyosarcoma", "Childhood Alveolar Rhabdomyosarcoma", "Childhood Embryonal Rhabdomyosarcoma", "Metastatic Childhood Soft Tissue Sarcoma", "Stage IV Adult Soft Tissue Sarcoma", "Untreated Childhood Rhabdomyosarcoma" ], "interventions": [ { "name": "Cixutumumab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dactinomycin", "type": "BIOLOGICAL" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Vincristine Sulfate Liposome", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "49 Years", "sex": "ALL", "summary": "Up to 49 Years" }, "enrollment_count": 175, "start_date": "2010-01", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2017-08-29", "last_synced_at": "2026-10-30T20:47:26.540Z", "location_count": 121, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01055314" }, { "nct_id": "NCT05735184", "title": "A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Mixed Lineage Leukemia Gene Mutation", "Refractory AML", "AML With Mutated NPM1", "Acute Myeloid Leukemia Recurrent", "Acute Myeloid Leukemia, in Relapse", "NPM1 Mutation", "KMT2Ar", "Myeloid Sarcoma", "Nucleophosmin 1-mutated Acute Myeloid Leukemia" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Quizartinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 420, "start_date": "2023-07-18", "completion_date": "2030-04", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-30T20:47:26.540Z", "location_count": 44, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05735184" }, { "nct_id": "NCT05534984", "title": "Study of Tecovirimat for Human Mpox Virus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "MPOX" ], "interventions": [ { "name": "Tecovirimat Oral Capsule", "type": "DRUG" }, { "name": "Placebo for Tecovirimat", "type": "DRUG" }, { "name": "Tecovirimat Oral Capsule (Open Label)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 719, "start_date": "2022-09-08", "completion_date": "2025-02-22", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-30T20:47:26.540Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05534984" }, { "nct_id": "NCT03701334", "title": "A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Early Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Endocrine Therapy (ET)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 5101, "start_date": "2018-12-07", "completion_date": "2030-05-29", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-30T20:47:26.540Z", "location_count": 73, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03701334" }, { "nct_id": "NCT01838863", "title": "Control of Major Bleeding After Trauma Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Trauma", "Hemorrhagic Shock" ], "interventions": [ { "name": "Type AB plasma", "type": "BIOLOGICAL" }, { "name": "Crystalloid fluid (standard of care for resuscitation)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Denver Health and Hospital Authority", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2014-04-07", "completion_date": "2017-04-03", "has_results": true, "last_update_posted_date": "2019-01-08", "last_synced_at": "2026-10-30T20:47:26.540Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01838863" }, { "nct_id": "NCT04274738", "title": "A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Waldenstrom's Macroglobulinemia" ], "interventions": [ { "name": "Mavorixafor", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "X4 Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2020-04-30", "completion_date": "2022-10-31", "has_results": false, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-10-30T20:47:26.540Z", "location_count": 4, "location_summary": "Denver, Colorado • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04274738" }, { "nct_id": "NCT00004638", "title": "Immunologic Aspects of the Pathogenesis of Chronic Sinusitis in Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sinusitis" ], "interventions": [ { "name": "pathogenesis study", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "National Center for Research Resources (NCRR)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "0 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "0 Years to 18 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-30T20:47:26.540Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004638" }, { "nct_id": "NCT05648500", "title": "A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "Cenerimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Viatris Innovation GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 470, "start_date": "2022-12-13", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-10-30", "last_synced_at": "2026-10-30T20:47:26.540Z", "location_count": 22, "location_summary": "Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more", "locations": [ { "city": "Huntington Park", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Clearwater", "state": "Florida" }, { "city": "DeBary", "state": "Florida" }, { "city": "Kissimmee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05648500" }, { "nct_id": "NCT00826904", "title": "Regulation Of Maternal Fuel Supply And Neonatal Adiposity", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fetal Macrosomia", "Gestational Diabetes" ], "interventions": [], "intervention_types": [], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "FEMALE", "summary": "18 Years to 35 Years · Female only" }, "enrollment_count": 59, "start_date": "2007-10", "completion_date": "2017-03-20", "has_results": false, "last_update_posted_date": "2019-11-05", "last_synced_at": "2026-10-30T20:47:26.540Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00826904" } ] }